LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Raising NovoCure (NVCR) FY 26 Rev. Estimate To 693.9 M From 691.4 M 2/12/2026 9:52:44 AM
  • Wedbush Is Increasing NovoCure (NVCR) Q4 26 Rev. Estimate To 208.9 M From 208.2 M 2/12/2026 9:52:18 AM
  • Wedbush Is Increasing NovoCure (NVCR) Q3 26 Rev. Estimate To 177.7 M From 176.8 M 2/12/2026 9:52:06 AM
  • Wedbush Is Raising NovoCure (NVCR) Q2 26 Rev. Estimate To 172.7 M From 171.9 M 2/12/2026 9:51:56 AM
  • Wedbush Is Increasing NovoCure (NVCR) Q1 26 Rev. Estimate To 134.7 M From 134.5 M 2/12/2026 9:51:42 AM
  • Wedbush Is Increasing NovoCure (NVCR) FY 26 Estimate To -1.29 From -1.31 2/12/2026 9:51:09 AM
  • Wedbush Is Increasing NovoCure (NVCR) Q4 26 Estimate To -0.07 From -0.08 2/12/2026 9:50:58 AM
  • Wedbush Is Raising NovoCure (NVCR) Q3 26 Estimate To -0.29 From -0.30 2/12/2026 9:50:37 AM
  • Wedbush Reiterates NovoCure (NVCR) At Neutral With $18 Price Target 2/12/2026 9:49:37 AM
  • FDA Approves Novocure's Optune Pax For Treating Locally Advanced Pancreatic Cancer; Stock Up 28% 2/11/2026 7:38:07 PM
  • Novocure Q4 Total Preliminary Net Revenues $174.4 mln, Increase Of 8% From Last Year 1/12/2026 7:03:36 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap